A medical device's intended purpose - what is the point?

Dr Simon Cumiskey
Considering a medical device's intended purpose

A clear idea of your medical device’s intended purpose is crucial in meeting the EU MDR regulatory requirements. Getting it right early in the development process is important, as it provides inputs to:

  1. Objectives of the Clinical Evaluation,
  2. Defining the SOTA,
  3. Design of clinical investigations,
  4. Equivalence claims,
  5. Evidence for conformity to relevant GSPRs.

A clinical evaluation should, according to its definition in Article 2(44) of the EU MDR, “verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer.”

But what is the intended purpose, and how does it interact with indications for use, claims, and intended clinical benefits? For each term, we will consider a fictional hip implant device.

Intended purpose

‘Intended purpose’ should describe what the device is used for and the effect of the device. Article 2(12) of the EU MDR defines ‘intended purpose’ as “the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation.”

All medical devices will have an intended purpose. In the case of a hip implant, the intended purpose could be for the replacement of native hip joints in adult patients with moderate to severe hip osteoarthritis.

Indication for use

‘Indication for use’ should describe the clinical condition that the device targets. MDCG 2020-6 defines the indication for use as “the clinical condition that is to be diagnosed, prevented, monitored, treated, alleviated, compensated for, replaced, modified or controlled by the medical device.”

Some devices, therefore, may not have an indication for use. An example would be a medical device intended to sterilise equipment. In the case of a hip implant, the indication for use could be hip osteoarthritis with an Oxford Hip Score less than 29.

Clinical benefit

‘Clinical benefit’ should describe the benefit to the patient from using the device in a quantifiable manner. Article 2(53) of the EU MDR defines clinical benefit as “the positive impact of a device on the health of an individual, expressed in terms of a meaningful, measurable, patient-relevant clinical outcome(s), including outcome(s) related to diagnosis, or a positive impact on patient management or public health.”

All devices will have a clinical benefit, but these can be either direct or indirect. In the case of a hip implant, the intended clinical benefit could be the reduction in pain VAS score by 25%. An example of a medical device with an indirect clinical benefit would be the scalpel used during the operation; a scalpel will not reduce pain in patients with osteoarthritis, but will facilitate insertion of the hip replacement and therefore lead to an improvement in pain VAS score.

Claims

‘Claims’ are not defined in the EU MDR, but Article 7 prohibits any information supplied by the manufacturer that may mislead the user with regard to the intended purpose, safety, or performance. Claims, therefore, can be derived from any manufacturer documents and should be supported by clinical evidence in the clinical evaluation.

Claims will encompass all of the intended use, indications for use, clinical benefits, as well as other terms not discussed in this article such as intended user, use environment, etc.

Summary

To briefly summarise each of the points above:

Intended purpose Is the use and effect of the device.
Indications for use Is the clinical condition that the device targets.
Clinical benefit Is the measurable impact on the patient.
Claims Derived from the above, plus any other claims made in marketing materials, IFU, etc.

For further information on how we can help you meet your MDR requirements please contact us for a free and confidential discussion.

Alternatively, for any general regulatory questions you need a quick answer to, have you tried our AI-powered MDR & MDCG chatbot? — it’s free and will answer your queries around the clock.

Related articles

  1. A poster frame for our Clinical Evaluation video series featuring Paul Hercock.

    Guide to Clinical Evaluation: Common Pitfalls & Useful Resources

    Part 5 - In the final video from this series, we explore five major pitfalls that often derail clinical evaluations.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  2. An EU flag on a pole flies between two US flags against a blue sky.

    Webinar: From USA to Europe - Accelerating Your Path to the Medical Device Market

    Join us on the 9th December 2025 to learn how to quickly transform your U.S. regulatory work into a compliant EU MDR submission.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  3. A US-style 'changes ahead' warning road sign.

    Device Modifications: When a Simple Change Becomes a Regulatory Nightmare

    As regulatory consultants we understand how minor modifications to a device can often cause disproportionate disruption.

    Kamiya Crabtree Kamiya Crabtree Regulatory Medical Writer
  4. Webinar announcement poster.

    Webinar: Regulatory & Cybersecurity Essentials for medical device software and AI-enabled devices

    Our webinar with Cyber Alchemy addressed bringing AI-enabled medical devices to market with both the right regulatory and cybersecurity foundations.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  5. A simple jigsaw with iconography representing growth printed on it.

    Leveraging Post-Market Surveillance Data for Continuous Improvement

    PMS isn’t just about compliance, it’s an opportunity for improvement, enhance patient safety & innovate.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  6. A poster frame for our Clinical Evaluation video series featuring Dr. W. Brambley.

    Guide to Clinical Evaluation: CEP Strategy & CER Structure

    Part 4 - We explore how these guide reviewers through the evidence that supports safey, performance, and conformity.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  7. A checklist being ticket-off in pen.

    The Critical Role of Pre-Submission Reviews in EU MDR Clinical Evaluations

    Ensuring your CER is robust and aligned with current standards is critical. How much Clinical Evidence is enough?

    Sandra Gopinath Sandra Gopinath Chief Regulatory Officer
  8. A poster frame for our Clinical Evaluation video series featuring Dr. W. Brambley.

    Guide to Clinical Evaluation: The State-of-the-Art (SOTA) Literature Review

    Part 3 - This is core of a sucessful submission. Will demystifies the process and explains how it supports clinical evaluation.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  9. An orange tabletop with wooden question mark blocks laid upon it.

    Regulatory Update: EU Borderline & Classification Manual for medical devices v4

    New examples sharpen the distinction between medical devices and other product categories, such as pharmacologically active substances and aesthetic-only products.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  10. A poster frame for our Clinical Evaluation video series featuring Dr. P. Boxall.

    Guide to Clinical Evaluation: Clinical Evaluation in Context

    Part 2 - A clinical evaluation demonstrates that a device is safe and effective, but achieving this requires more than simply compiling studies.

    Dr Peter Boxall Dr Peter Boxall Lead Medical Writer

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP